[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
The Cutting Edge
November 2001

Treatment of Diffuse Plane Xanthoma of the Face With the Erbium:YAG Laser

Author Affiliations
 

GEORGE J.HRUZAMDDEE ANNAGLASERMDELAINESIEGFRIEDMD

Arch Dermatol. 2001;137(11):1413-1415. doi:10.1001/archderm.137.11.1413
REPORT OF A CASE

A 23-year-old woman presented with an 8-year history of progressive diffuse plane xanthomata of the face and neck. Beginning at the earlobes and neck, these yellowish maculopapular lesions had spread over the whole face and neck region, making the patient look as if she were wearing a mask (Figure 1A and Figure 2A). Histologic features were typical for plane xanthoma with multiple foam cells surrounding the sebaceous glands and hair follicles in the whole dermis, in parts reaching the dermis-fat junction. Electron microscopic findings showed foamy histiocyte-like cells and solitary infiltrating giant cells in the dermis. Triglyceride, lipoprotein, and cholesterol levels were normal. Other reasons (eg, monoclonal gammopathies, lymphoproliferative diseases, or normolipemic xanthomatous syndromes) were excluded as well by findings from lipid- and immunoelectrophoresis, blood cell counts, radiography of the skull, and electron microscopy, which were consistent with diffuse idiopathic plane xanthoma (group II, type 1).

Figure 1.
A, Full face 8 weeks after the treatment of the test areas before the first full lesional treatment. B, Full face 1 year after the second full lesional treatment. Almost complete clearance on forehead, periorbital, and nasolabial areas; persisting brownish xanthoma on the upper lip, cheeks, and chin.

A, Full face 8 weeks after the treatment of the test areas before the first full lesional treatment. B, Full face 1 year after the second full lesional treatment. Almost complete clearance on forehead, periorbital, and nasolabial areas; persisting brownish xanthoma on the upper lip, cheeks, and chin.

Figure 2.
A, Forehead area before the first full lesional treatment. Almost complete clearance in the test areas (no hypopigmentation compared with the untreated area just above the right eyebrow). B, Close-up of forehead area 1 year after the last full lesional treatment.

A, Forehead area before the first full lesional treatment. Almost complete clearance in the test areas (no hypopigmentation compared with the untreated area just above the right eyebrow). B, Close-up of forehead area 1 year after the last full lesional treatment.

THERAPEUTIC CHALLENGE

This patient was disturbed by her facial disfigurement. Because of the cobblestonelike surface of the lesions, she was not able to put on makeup and felt as though she was wearing a mask. Our aim was to remove the widespread lesions with a low risk of scarring.

SOLUTION

We proposed to remove the plane xanthoma with a resurfacing laser. Two 1-cm2 test areas on the chin and forehead were treated on one side with an Erbium (Er):YAG laser (MCL 29; Aesculap-Meditec GmbH, Heroldsberg, Germany) (laser wavelength, 2.94 µm; pulse length, 250 microseconds; repetition rate, 7-10 Hz; spot size, 4 mm; pulse energy, 500 mJ; fluence, 4 J/cm2) and on the other side with a continuous-wave (CW) carbon dioxide (CO2) laser (Sharplan 1020 [50-mm handpiece]; Sharplan Laser Industries, Tel Aviv, Israel) with a 1- and 2-mm spot size at 5 W. In each case, the lesions were ablated into the superficial dermis until papillary bleeding occurred.

After 3 months, both test areas showed resolution of the lesions without recurrence (Figure 1A and Figure 2A). Because the Er:YAG laser–treated area had healed faster, the Er:YAG laser was used for full-face resurfacing under general anesthesia. No pretreatment with hydroquinone was done. Perioperatively, herpes prophylaxis with acyclovir (200 mg by mouth 3 times a day) was prescribed for 10 days. Postoperatively, hydrocolloid dressings were applied until the beginning of reepithelialization, followed by the application of petrolatum gauze and antiseptic ointment (Bepanthen; F. Hoffmann-La Roche Ltd, Basel, Switzerland) for 1 week. For further postoperative care, we recommended an ointment containing ascorbic acid and sun protection.

After 2 months a retreatment of the persisting parts of the xanthomas was performed, but not all of the lesions could be completely removed (Figure 1B and Figure 2B, yellowish areas). One year after the second laser session, the persisting areas of xanthoma on the upper lip, cheeks, and chin had remained flat and smooth, showing no tendency to recur. In the periorbital area where the xanthomas had been totally removed, no recurrences were noted. Textural changes or scarring were absent (Figure 1B and Figure 2B). A third Er:YAG laser session is planned to further improve the results. Because of the high risk of scarring, we did not treat the neck and earlobe region. Presently, the patient is pleased with these partial results. Because of the smoothened surface, she can now apply makeup without problems to cover the remaining discoloration.

COMMENT

Single plane xanthomas are yellow to cream-colored patches and plaques associated with xanthelasma palpebrarum and normal plasma lipid levels.1 Histologically, clusters of xanthoma cells with foamy cytoplasm surrounding blood vessels are in the dermis. Touton or foreign body giant cells are absent.

Diffuse plane xanthomas can be divided into 2 groups: group I is associated with increased serum levels of lipids due to familial hyperlipemia or biliary cirrhosis, whereas group II has normal lipid levels.2 The latter can further be divided into 3 subtypes: type 13 is idiopathic, type 2 is associated with lymphoproliferative diseases,46 and type 3 is associated with abnormalities of the structure or content of lipoproteins. All types can appear principally in a widespread or diffuse pattern, but group II type 2 is more likely to appear in a diffuse pattern.

Ablative lasers such as the scanned CW CO2, pulsed CO2, and Er:YAG lasers are safe and effective devices for the removal of epidermal or superficial dermal lesions.7 The scanned CW and pulsed CO2 lasers are classic devices for skin resurfacing.8 The thermal effect leading to collagen shrinkage is desired in the treatment of rhytids because it seems to enhance tightening.9,10 In areas of thin skin such as the periorbital area, these lasers have to be used very cautiously to prevent scarring or an ectropion of the eyelid. The Er:YAG laser is a purely ablative laser with a much smaller thermal coagulation zone due to its high absorption in tissue9,11,12

All therapeutic options in the treatment of plane xanthoma are based on mechanical removal by excision, chemabrasion, dermabrasion, or ablative laser therapy13,14 We chose to remove the lesions by laser ablation. Because of its high scarring risk, the CW CO2 laser has to be used very carefully. The scanned CW CO2 and pulsed CO2 laser were considered because of their reduced risk of scarring (coagulation zone up to 200 µm).7 However, we chose the Er:YAG laser because of the faster healing seen in the test areas15,16 Additionally, the phenomenon of skin tightening by collagen shrinkage (an effect seen in CO2 laser resurfacing) was not important in this case.

With the Er:YAG laser, no further treatment is possible as soon as papillary bleeding occurs. The risk of scarring is therefore reduced to a minimum. Another advantage of the "cold ablative" technique with the Er:YAG laser over the use of the scanned CW CO2 and pulsed CO2 lasers is in the duration of postlaser erythema and hypopigmentation or hyperpigmentation: the Er:YAG laser has the shortest duration, followed by the pulsed CO2 laser and then the scanned CW CO2 laser.1518 Using the cold ablative technique (with reported coagulation zones of 5 to 50 µm12,17,18), the reepithelization time of approximately 6 days is faster than that of CW CO2 laser–treated areas.

In our patient, the test sites treated with the Er:YAG and CW CO2 lasers showed similar clearance of the lesions. Knowing that the risk of scarring would be higher with the CW CO2 laser, we chose to perform the full-face treatment with the Er:YAG laser. In 2 sessions the lesions were removed almost completely. Six days after each of the laser treatments, reepithelialization was complete. No scarring or textural changes of the skin could be seen. Due to the superficial ablation of the lesions, a recurrence of the plane xanthomas would be expected to occur. However, almost 1 year later the patient shows no recurrence of the xanthoma.

Because diffuse plane xanthoma can be a precursor of monoclonal gammopathy and associated myeloproliferative disorders, annual immunoelectrophoresis should be performed to monitor for the onset of these diseases. Er:YAG laser therapy of facial diffuse plane xanthoma is an effective ablative treatment that shows acceptable rates of adverse effects and fast reepithelialization.

Back to top
Article Information

Accepted for publication March 28, 2001.

Corresponding author: Ulrich Hohenleutner, MD, Department of Dermatology, University of Regensburg, 93053 Regensburg, Germany (e-mail: Ulrich. Hohenleutner@klinik.uni-regensburg.de).

References
1.
Daoud  MSLust  JAKyle  RAPittelkow  MR Monoclonal gammopathies and associated skin disorders. J Am Acad Dermatol. 1999;40507- 535Article
2.
Williford  PMWhite  WLJorizzo  JLGreer  K The spectrum of normolipemic plane xanthoma. Am J Dermatopathol. 1993;15572- 575Article
3.
Horiuchi  YIto  A Normolipemic papuloeruptive xanthomatosis in an infant. J Dermatol. 1991;18235- 239
4.
Ginarte  MPeteiro  CToribio  J Generalized plane xanthoma and idiopathic Bence-Jones proteinuria. Clin Exp Dermatol. 1997;22192- 194Article
5.
Sharpe  PCDawson  JFO'Kane  MJWalsh  MYMcMillan  SANicholls  DP Diffuse plane xanthomatosis associated with a monoclonal band displaying anti-smooth muscle antibody activity. Br J Dermatol. 1995;133961- 966Article
6.
Buezo  GFPorras  JIFraga  JSanchez  EAragues  MDauden  E Coexistence of diffuse plane normolipaemic xanthoma and amyloidosis in a patient with monoclonal gammopathy. Br J Dermatol. 1996;135460- 462Article
7.
Fleming  D Controversies in skin resurfacing: the role of erbium. J Cutan Laser Ther. 1999;115- 21Article
8.
Kaufmann  RHartmann  AHibst  R Cutting and skin-ablative properties of pulsed mid-infrared laser surgery. J Dermatol Surg Oncol. 1994;20112- 118Article
9.
Khatri  KARoss  VGrevelink  JMMagro  CMAnderson  RR Comparison of erbium:YAG and carbon dioxide lasers in resurfacing of facial rhytides. Arch Dermatol. 1999;135391- 397Article
10.
Ross  EVMcKinlay  JRAnderson  RR Why does carbon dioxide resurfacing work? a review. Arch Dermatol. 1999;135444- 454Article
11.
Kaufmann  RHibst  R Pulsed 2.94-microns erbium-YAG laser skin ablation-experimental results and first clinical application. Clin Exp Dermatol. 1990;15389- 393Article
12.
Hohenleutner  UHohenleutner  SBäumler  WLandthaler  M Fast and effective skin ablation with an Er:YAG Laser: determination of ablation rates and thermal damage zones. Lasers Surg Med. 1997;20242- 247Article
13.
Fulton  JE Dermabrasion, chemabrasion and laser abrasion. Dermatol Surg. 1996;22619- 628
14.
Carpo  BGGrevelink  SVBrady  SGellis  SGrevelink  JM Treatment of cutaneous lesions of xanthoma disseminatum with a CO2 laser. Dermatol Surg. 1999;25751- 754Article
15.
Fitzpatrick  REWilliams  BGoldman  MP Preoperative anesthesia and postoperative considerations in laser resurfacing. Semin Cutan Med Surg. 1996;15170- 176Article
16.
Waldorf  HAKauvar  ANGeronemus  R Skin resurfacing of fine and deep rhytides using a char-free carbon dioxide laser in 47 patients. Dermatol Surg. 1995;21940- 946
17.
Weinstein  C Computerized scanning erbium:YAG laser for skin resurfacing. Dermatol Surg. 1998;2483- 89
18.
Kaufmann  RHibst  R Pulsed erbium:YAG laser ablation in cutaneous surgery. Lasers Surg Med. 1996;19324- 330Article
×